ClinicalTrials.gg
Enrolling by invitationNCT03197363Bialystok+Updated Oct 16, 2026

Białystok PLUS - Polish Longitudinal University Study

An observational study in Cardiovascular Diseases, Diabetes and Neuro-Degenerative Disease, sponsored by Medical University of Bialystok. Enrolling by invitation at 1 site in Poland. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Medical University of Bialystok · Observational

How we know

Updated Oct 16, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
8,320
Ages
20 Years to 80 Years
Sex
All
01

Study summary

The main goal of the study is to provide a unique multidimensional picture of the health of the population with simultaneous optimal standards of sampling, processing and storing of data and biomaterial that will allow discovering novel mechanisms in the development and progression of common civilization diseases. In the effect it will improve prevention, diagnosis and treatment.

Read the detailed description

One of the objectives of this project is to obtain comprehensive information on the health status (including subclinical disorders), genomics, risk factors, health behavior and sociodemographic data from large, representative sample of population of Białystok city inhabitants.

The study will assess many systems, the major emphasis will be given to the most common diseases associated with modern lifestyle (civilization diseases): cardiovascular, metabolic and endocrine, neurodegenerative, neoplastic and pulmonary. There are many interactions between them that might be missed when not analyzed together. Apart from those most common diseases we will also asses others, including allergies, airway dysfunction - both upper and lower, urinary incontinency, gastrointestinal disorders, eye diseases. There may be many common underlying mechanisms of the diseases that now seem to be distant and independent, because of insufficient knowledge.

Health status assessment will refer to many areas of medicine and will include clinical data, medical images, as well as biological samples and voice recording samples. We plan to combine imaging (fundoscopy, ultrasound examinations of heart, vessels, thyroid, liver) with state of the art functional studies (AGE measurement, pulse wave velocity, central pressure, plethysmography with the analysis of diffusing capacity of lung for carbon monoxide and NO concentration, spiroergometry, oral glucose tolerance test.

Voice samples will be analyzed in the speech analysis software, it will help in the diagnosis of civilization diseases such as diabetes, depression, and atherosclerosis.

Participants will fill in detailed questionnaires that will provide information about their family history, dietary habits, socioeconomic status, stress coping strategies, lifestyle, exposure to harmful environment, various symptoms, history of diagnosed diseases and treatment.

The study is designed as prospective, so in the future, additional information on occurrence of diseases or deaths will allow to estimate disease incidence, morbidity or mortality in studied population.

02

Conditions studied

  • Cardiovascular Diseases
  • Diabetes
  • Neuro-Degenerative Disease
  • Obesity
  • Pulmonary Disease
  • Neoplastic Disease

Keywords

  • Civilization diseases
  • Cardiovascular Risk Factor
  • Population study
  • Intestinal microbiome
  • Oral microbiome
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 8,320 is above the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Medical University of Bialystok is the lead sponsor of 72 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Inhabitants of Bialystok (selected from the registry of Bialystok inhabitants). Stratified sampling will be performed, based on sex and age strata (10-year intervals) in order the sample to be representative for gender and age distribution in Bialystok population.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • inhabitants of Bialystok (randomly selected from the registry of Bialystok inhabitants)
  • age 20-80

Exclusion criteria

Exclusion Criteria:

  • disagreement of the invited person
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
8,320 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Białystok PLUS

    Participation in the study wwas offered to 8320 inhabitants of Bialystok aged 20-80 years. They were randomly selected from the registry of Bialystok inhabitants. Actual number of assessed individuals was 3527. The goal of study is to discover novel risk factors and mechanisms underlying civilization diseases.

    Other: Discovering novel risk factors.

Interventions

  • OtherDiscovering novel risk factors.

    The study protocol includes multiple imaging and functional investigations (including heart, carotid, thyroid, liver ultrasound, fundoscopy, plethysmography, pulse wave velocity, ankle-brachial index, ECG, body composition measured by bioimpedance and dual energy x-ray absorptiometry, anthropometric assessment, rhinometry, hand grip test, oral glucose tolerance test, advance glycation end-products measurement, voice recording. There will be a detailed and verified questionnaires concerning various activities of the subject: physical activity, depression, sino-nasal symptoms, prostate hypertrophy, female urinary tract symptoms, quality of life, smoking and drinking addiction, hirsutism.

06

What researchers measure

Primary outcomes

  1. Death or the occurrence of diseases

    Death or the occurrence of diseases: cardiovascular diseases, diabetes, neuro-degenerative diseases, obesity, pulmonary diseases, neoplastic diseases

    Time frame: 5 years

07

Study locations

1 site
  • Population Research Center, Medical University of Bialystok
    Bialystok, 15-274, Poland
08

References and documents

Individual participant data

Plan to share: Yes — Scientists and researchers who collaborate on Bialystok PLUS study organization have access to results of examinations and analyses of biological material. Personal data are protected and only designated persons have access to them.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2018 (actual). Primary completion is estimated for Dec 2030, 145 months after the start.

Of 583 non-industry observational studies under Cardiovascular Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 196. This study's planned 145 months is above that.

Counting every sponsor, half of 667 studies reached it within 62 months; a quarter within 24 and three quarters within 192.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Dec 2024 → Dec 2030 and completion Dec 2029 → Jun 2034.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2017
First posted
Jun 23, 2017
StartActual
Nov 5, 2018
Primary completionEst.
Dec 2030was Dec 2024
CompletionEst.
Jun 2034was Dec 2029
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Population Research Center, Medical University of Bialystok · Bialystok, Poland
Show 1 removed
  • Medical University of Bialystok · Białystok, Poland
Oct 16, 2026
Primary completion
Dec 2024→Dec 2030
Oct 16, 2026
Study completion
Dec 2029→Jun 2034
Oct 16, 2026
Enrollment
10000→8320
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    1 site added, 1 site removed
    Show site
    • Population Research Center, Medical University of Bialystok · Bialystok, Poland
    Show 1 removed
    • Medical University of Bialystok · Białystok, Poland
    Primary completion Dec 2024→Dec 2030
    Study completion Dec 2029→Jun 2034
    Enrollment 10000→8320
    + 3 other changes: verification date, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03197363
Lead sponsor
Medical University of Bialystok
Collaborators
University Medicine Greifswald, City of Białystok, Marshall's Office of Podlaskie Voivodship
Responsible party
Sponsor
First posted
Jun 23, 2017
Start date
Nov 5, 2018
Primary completion
Dec 2030 (estimated)
Completion
Jun 2034 (estimated)
Last update
Oct 16, 2026

Study contacts

Karol A. Kaminski, Professor
principal investigator · Medical University of Bialystok

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion